Cite
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
MLA
Cortes, Jorge E., et al. “Patient-Reported Outcomes in the Phase 3 BFORE Trial of Bosutinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.” Journal of Cancer Research & Clinical Oncology, vol. 145, no. 6, June 2019, pp. 1589–99. EBSCOhost, https://doi.org/10.1007/s00432-019-02894-3.
APA
Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D.-W., Milojkovic, D., le Coutre, P., Garcia-Gutierrez, V., Crescenzo, R., Mamolo, C., Reisman, A., Hochhaus, A., & Brümmendorf, T. H. (2019). Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. Journal of Cancer Research & Clinical Oncology, 145(6), 1589–1599. https://doi.org/10.1007/s00432-019-02894-3
Chicago
Cortes, Jorge E., Carlo Gambacorti-Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Dragana Milojkovic, et al. 2019. “Patient-Reported Outcomes in the Phase 3 BFORE Trial of Bosutinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.” Journal of Cancer Research & Clinical Oncology 145 (6): 1589–99. doi:10.1007/s00432-019-02894-3.